BearDownAZ,
I found this post,... is it something to worry about or nothing,..?
Thanks!
DSMB #7 - Aug 7 ' 1st paragraph, last sentence: The DSMB reviewed available study data and noted that no safety or efficacy concerns were identified, and will conduct additional periodic reviews. Resverlogix, the clinical steering committee, and all investigators remain blinded to the trial data.
Now, DSMB #8 - today: 1st paragraph:
The DSMB reviewed available safety data and commented that no safety concerns were identified. Resverlogix, the clinical steering committee, and all investigators remain blinded to the trial data.
DSMB #6 - The DSMB reviewed available study data and noted that no safety or efficacy concerns were identified, and will conduct additional periodic reviews. Resverlogix, the clinical steering committee, and all investigators remain blinded to the trial data.
note that they dropped the reference to "NO EFFICACY CONCERNS were identified."
is this a big deal, or am i just reading something into maybe a sloppy NR!?!? with our stellar mgmnt record, it could go either way!